{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:29:41Z","timestamp":1792787381631,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the-art treatment of mantle cell lymphoma (MCL). With numerous therapeutic innovations currently entering the MCL treatment landscape, guidance for indication, sequencing and application of cellular therapies is of key importance. To address this practical need, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonisation and Guidelines Committee convened an international expert meeting in Berlin on Sept 29\/30, 2025. EBMT provided funding and logistical support. Two appointed chairpersons invited experts in MCL and cellular therapy, who completed three work packages devoted to the three types of cellular therapy. A literature search was performed beforehand and suitable published evidence was considered collectively in structured discussions and consensus-building exercises. The recommendations developed as a result of this process provide a sound basis for practical counseling and decision-making in the care of patients with treatment-na\u00efve and relapsed\/refractory MCL.<\/jats:p>","DOI":"10.1038\/s41409-026-02963-5","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:39:06Z","timestamp":1783553946000},"page":"1151-1161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9288","authenticated-orcid":false,"given":"Gloria","family":"Iacoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2991-3474","authenticated-orcid":false,"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7261-2765","authenticated-orcid":false,"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5519-9154","authenticated-orcid":false,"given":"Isabel","family":"Ortega-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2963_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2014.223","volume":"29","author":"S Robinson","year":"2015","unstructured":"Robinson S, Dreger P, Caballero D, et al. The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015;29:464\u201373.","journal-title":"Leukemia"},{"key":"2963_CR2","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1038\/s41409-021-01288-9","volume":"56","author":"PN Munshi","year":"2021","unstructured":"Munshi PN, Hamadani M, Kumar A, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transpl. 2021;56:2911\u201321.","journal-title":"Bone Marrow Transpl"},{"key":"2963_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41409-025-02599-x","volume":"60","author":"P Dreger","year":"2025","unstructured":"Dreger P, Ahmed S, Bazarbachi A, et al. How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives. Bone Marrow Transpl. 2025;60:759\u201368.","journal-title":"Bone Marrow Transpl"},{"key":"2963_CR4","first-page":"720","volume":"27","author":"PN Munshi","year":"2021","unstructured":"Munshi PN, Hamadani M, Kumar A, et al. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transpl Cell Ther. 2021;27:720\u20138.","journal-title":"Transpl Cell Ther"},{"key":"2963_CR5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41409-023-01958-w","volume":"58","author":"I Yakoub-Agha","year":"2023","unstructured":"Yakoub-Agha I, Greco R, Onida F, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transpl. 2023;58:696\u2013700.","journal-title":"Bone Marrow Transpl"},{"key":"2963_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bjh.19131","volume":"204","author":"TA Eyre","year":"2024","unstructured":"Eyre TA, Bishton MJ, McCulloch R, et al. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204:108\u201326.","journal-title":"Br J Haematol"},{"key":"2963_CR7","doi-asserted-by":"publisher","first-page":"e70233","DOI":"10.1002\/hem3.70233","volume":"9","author":"M Jerkeman","year":"2025","unstructured":"Jerkeman M, Aurer I, Campo E, et al. EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma. Hemasphere. 2025;9:e70233.","journal-title":"Hemasphere"},{"key":"2963_CR8","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","volume":"36","author":"TA Eyre","year":"2025","unstructured":"Eyre TA, Cwynarski K, d\u2019Amore F, et al. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:1263\u201384.","journal-title":"Ann Oncol"},{"key":"2963_CR9","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903\u201310.","journal-title":"Blood"},{"key":"2963_CR10","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","volume":"105","author":"S Ferrero","year":"2020","unstructured":"Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105:1604\u201312.","journal-title":"Haematologica"},{"key":"2963_CR11","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","volume":"87","author":"TC Greiner","year":"1996","unstructured":"Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87:4302\u201310.","journal-title":"Blood"},{"key":"2963_CR12","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","volume":"37","author":"G Scheubeck","year":"2023","unstructured":"Scheubeck G, Jiang L, Hermine O, et al. Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia. 2023;37:1887\u201394.","journal-title":"Leukemia"},{"key":"2963_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14241","volume":"175","author":"CW Eskelund","year":"2016","unstructured":"Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175:410\u20138.","journal-title":"Br J Haematol"},{"key":"2963_CR14","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","volume":"34","author":"E Hoster","year":"2016","unstructured":"Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016;34:1386\u201394.","journal-title":"J Clin Oncol"},{"key":"2963_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.14870","volume":"179","author":"S Rule","year":"2017","unstructured":"Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179:430\u20139.","journal-title":"Br J Haematol"},{"key":"2963_CR16","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(25)01432-1","volume":"406","author":"DJ Lewis","year":"2025","unstructured":"Lewis DJ, Jerkeman M, Sorrell L, et al. Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial. Lancet. 2025;406:1953\u201368.","journal-title":"Lancet"},{"key":"2963_CR17","doi-asserted-by":"publisher","first-page":"e70101","DOI":"10.1002\/hem3.70101","volume":"9","author":"E Forsgren","year":"2025","unstructured":"Forsgren E, Jorgensen RRK, Bentzen H, et al. Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: long-term follow-up of the Nordic lymphoma group MCL6 Philemon trial. Hemasphere. 2025;9:e70101.","journal-title":"Hemasphere"},{"key":"2963_CR18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/bjh.15643","volume":"185","author":"C Visco","year":"2019","unstructured":"Visco C, Tisi MC, Evangelista A, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185:940\u20134.","journal-title":"Br J Haematol"},{"key":"2963_CR19","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","volume":"5","author":"CW Eskelund","year":"2021","unstructured":"Eskelund CW, Dimopoulos K, Kolstad A, et al. Detailed long-term follow-up of patients who relapsed after the Nordic mantle cell lymphoma trials: MCL2 and MCL3. Hemasphere. 2021;5:e510.","journal-title":"Hemasphere"},{"key":"2963_CR20","first-page":"78","volume":"15","author":"C Sarkozy","year":"2025","unstructured":"Sarkozy C, Chartier L, Ribrag V, et al. Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study. Blood. Cancer J. 2025;15:78.","journal-title":"Cancer J"},{"key":"2963_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.clml.2023.12.006","volume":"24","author":"A Rezazadeh","year":"2024","unstructured":"Rezazadeh A, Pruett J, Detzner A, et al. Immunoglobulin high-throughput sequencing (Ig-HTS) minimal residual disease (MRD) analysis is an effective surveillance tool in patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2024;24:254\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2963_CR22","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood-2024-212973","volume":"144","author":"TS Fenske","year":"2024","unstructured":"Fenske TS, Wang XV, Till BG, et al. Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma patients in first complete remission with undetectable minimal residual disease (uMRD): initial report from the ECOG-ACRIN EA4151 Phase 3. Blood. 2024;144:LBA\u20136.","journal-title":"Blood"},{"key":"2963_CR23","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2963_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.18697","volume":"201","author":"MR Wilson","year":"2023","unstructured":"Wilson MR, Barrett A, Cheah CY, Eyre TA. How I manage mantle cell lymphoma: indolent versus aggressive disease. Br J Haematol. 2023;201:185\u201398.","journal-title":"Br J Haematol"},{"key":"2963_CR25","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gine E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293\u2013306.","journal-title":"Lancet"},{"key":"2963_CR26","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1200\/JCO-25-00146","volume":"43","author":"TA Eyre","year":"2025","unstructured":"Eyre TA, Cheah CY, Sarkozy C, Kumar A, Le GS. Mantle cell lymphoma: optimal treatment with Bruton tyrosine kinase-targeted approaches. J Clin Oncol. 2025;43:2300\u201310.","journal-title":"J Clin Oncol"},{"key":"2963_CR27","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","volume":"60","author":"R Greco","year":"2025","unstructured":"Greco R, Ruggeri A, McLornan DP, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transpl. 2025;60:1499\u2013525.","journal-title":"Bone Marrow Transpl"},{"key":"2963_CR28","doi-asserted-by":"crossref","unstructured":"van Meerten T, Kersten MJ, Iacoboni G et al. Brexucabtagene autoleucel for BTKi-naive relapsed\/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3. Blood. 2025;147:1302\u20131314.","DOI":"10.1182\/blood.2025029734"},{"key":"2963_CR29","doi-asserted-by":"crossref","unstructured":"Shah NN, Colina AS, Johnson BD et al. Phase I\/II study of adaptive manufactured lentiviral anti-CD20\/anti-CD19 chimeric antigen receptor T cells for relapsed, refractory mantle cell lymphoma. J Clin Oncol. 2025;43:2285\u20132295.","DOI":"10.1200\/JCO-24-02158"},{"key":"2963_CR30","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.bbmt.2020.04.025","volume":"26","author":"ML Schubert","year":"2020","unstructured":"Schubert ML, Dietrich S, Stilgenbauer S, et al. Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2020;26:1575\u201380.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2963_CR31","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41409-025-02541-1","volume":"60","author":"MA Kharfan-Dabaja","year":"2025","unstructured":"Kharfan-Dabaja MA, Mohty R, Easwar N, et al. Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. Bone Marrow Transpl. 2025;60:632\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2963_CR32","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1182\/bloodadvances.2024015014","volume":"9","author":"N Ahmed","year":"2025","unstructured":"Ahmed N, Thiruvengadam S, Hamadani M, et al. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025;9:5382\u201396.","journal-title":"Blood Adv"},{"key":"2963_CR33","doi-asserted-by":"publisher","first-page":"e1006","DOI":"10.1016\/S2352-3026(23)00307-1","volume":"10","author":"P Dreger","year":"2023","unstructured":"Dreger P, Corradini P, Gribben JG, et al. CD19-directed CAR-T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach. Lancet Haematol. 2023;10:e1006\u2013e1015.","journal-title":"Lancet Haematol"},{"key":"2963_CR34","first-page":"581.e1","volume":"28","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Locke FL, Ma L, et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B-cell lymphoma in the United States. Transpl Cell Ther. 2022;28:581.e1\u2013581.e8.","journal-title":"Transpl Cell Ther"},{"key":"2963_CR35","doi-asserted-by":"crossref","unstructured":"Beitinjaneh A, Gupta S, Furqan F et al. Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R\/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel). Blood. 2025;144:3606.","DOI":"10.1182\/blood-2025-3606"},{"key":"2963_CR36","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/bloodadvances.2023010003","volume":"7","author":"RJ Lin","year":"2023","unstructured":"Lin RJ, Kim SJ, Brown S, et al. Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma. Blood Adv. 2023;7:3501\u20135.","journal-title":"Blood Adv"},{"key":"2963_CR37","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/bloodadvances.2024012727","volume":"8","author":"SJ Yates","year":"2024","unstructured":"Yates SJ, Cursio JF, Artz A, et al. Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024;8:3785\u201397.","journal-title":"Blood Adv"},{"key":"2963_CR38","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Mu\u00f1oz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"2963_CR39","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41:2594\u2013606.","journal-title":"J Clin Oncol"},{"key":"2963_CR40","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1002\/hem3.87","volume":"8","author":"MA O\u2019Reilly","year":"2024","unstructured":"O\u2019Reilly MA, Wilson W, Burns D, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis. Hemasphere. 2024;8:e87.","journal-title":"Hemasphere"},{"key":"2963_CR41","doi-asserted-by":"crossref","unstructured":"Simon L, Vucinic V, Rejeski K, et al. Results of brexucabtagene-autoleucel for patients with relapsed\/refractory mantle cell lymphoma in the routine setting in Germany and Switzerland. Bone Marrow Transplant. 2026;61:480\u2013483.","DOI":"10.1038\/s41409-025-02789-7"},{"key":"2963_CR42","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke FL, Filosto S, Chou J, et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy, chemotherapy and transplant in large B cell lymphoma. Nat Med. 2024;30:507\u201318.","journal-title":"Nat Med"},{"key":"2963_CR43","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/bloodadvances.2023012255","volume":"8","author":"G Ahmed","year":"2024","unstructured":"Ahmed G, Alsouqi A, Szabo A, et al. CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024;8:3528\u201331.","journal-title":"Blood Adv"},{"key":"2963_CR44","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/ajh.27056","volume":"98","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Wang Y, Albanyan O, et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023;98:1699\u2013710.","journal-title":"Am J Hematol"},{"key":"2963_CR45","doi-asserted-by":"crossref","unstructured":"Frenking JH, Zhou X, Wagner V et al. EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma. J Immunother Cancer 2024;12:e009220.","DOI":"10.1136\/jitc-2024-009220"},{"key":"2963_CR46","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.3324\/haematol.2023.284786","volume":"109","author":"C Herbaux","year":"2024","unstructured":"Herbaux C, Bret C, Bachy E, et al. Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. Haematologica. 2024;109:3745\u201350.","journal-title":"Haematologica"},{"key":"2963_CR47","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.23.02214","volume":"42","author":"M Wang","year":"2024","unstructured":"Wang M, Siddiqi T, Gordon LI, et al. Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I Multicenter Seamless Design Study. J Clin Oncol. 2024;42:1146\u201357.","journal-title":"J Clin Oncol"},{"key":"2963_CR48","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib a covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988\u201397.","journal-title":"J Clin Oncol"},{"key":"2963_CR49","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Mu\u00f1oz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41:555\u201367.","journal-title":"J Clin Oncol"},{"key":"2963_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Martin-Lopez AA, et al. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol. 2024;42:205\u201317.","journal-title":"J Clin Oncol"},{"key":"2963_CR51","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.1182\/bloodadvances.2024013726","volume":"8","author":"V Camus","year":"2024","unstructured":"Camus V, Houot R, Brisou G, et al. Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy. Blood Adv. 2024;8:5371\u201381.","journal-title":"Blood Adv"},{"key":"2963_CR52","first-page":"877","volume":"137","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill S, Morschhauser F, Chiron D, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial. B. 2021;137:877\u201387.","journal-title":"B."},{"key":"2963_CR53","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","volume":"26","author":"M Wang","year":"2025","unstructured":"Wang M, Jurczak W, Trneny M, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025;26:200\u201313.","journal-title":"Lancet Oncol"},{"key":"2963_CR54","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.23.02470","volume":"43","author":"TJ Phillips","year":"2025","unstructured":"Phillips TJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a Phase I\/II study. J Clin Oncol. 2025;43:318\u201328.","journal-title":"J Clin Oncol"},{"key":"2963_CR55","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127:1117\u201327.","journal-title":"Blood"},{"key":"2963_CR56","first-page":"673","volume":"143","author":"A Minson","year":"2024","unstructured":"Minson A, Hamad N, Cheah CY, et al. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. B. 2024;143:673\u201384.","journal-title":"B."},{"key":"2963_CR57","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33:259\u201375.","journal-title":"Ann Oncol"},{"key":"2963_CR58","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30:2667\u201378.","journal-title":"Nat Med"},{"key":"2963_CR59","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.3324\/haematol.2019.223016","volume":"105","author":"C Bailly","year":"2020","unstructured":"Bailly C, Carlier T, Berriolo-Riedinger A, et al. Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. Haematologica. 2020;105:e33\u2013e36.","journal-title":"Haematologica"},{"key":"2963_CR60","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1182\/bloodadvances.2025016778","volume":"9","author":"X Deschenes-Simard","year":"2025","unstructured":"Deschenes-Simard X, Bromberg M, Devlin SM, et al. Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma. Blood Adv. 2025;9:5571\u201384.","journal-title":"Blood Adv"},{"key":"2963_CR61","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677\u201384.","journal-title":"Blood"},{"key":"2963_CR62","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma following intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a non-randomized phase-II multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687\u201393.","journal-title":"Blood"},{"key":"2963_CR63","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565\u201375.","journal-title":"Lancet"},{"key":"2963_CR64","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1182\/blood-2024-200735","volume":"144","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn JK, Gine E, et al. Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network. Blood. 2024;144:240.","journal-title":"Blood"},{"key":"2963_CR65","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2024-201441","volume":"144","author":"M Ladetto","year":"2024","unstructured":"Ladetto M, Gutmair K, Doorduijn JK, et al. Impact of Rituximab maintenance added to ibrutinib-containing regimens with and without ASCT in younger, previously untreated MCL patients: an analysis of the triangle data embedded in the multiply project. Blood. 2024;144:237.","journal-title":"Blood"},{"key":"2963_CR66","doi-asserted-by":"crossref","unstructured":"Ragaini S, Gutmair K, Moia R et al. Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project. Blood 2025;146:5299.","DOI":"10.1182\/blood-2025-5299"},{"key":"2963_CR67","doi-asserted-by":"crossref","unstructured":"Martin P, Cohen JB, Wang M et al. Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts. J Clin Oncol. 2023;41:541\u2013554.","DOI":"10.1200\/JCO.21.02698"},{"key":"2963_CR68","doi-asserted-by":"crossref","unstructured":"Houot R, Bachy E, Cartron G et al. Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. Nat Med. 2023;29:2593\u20132601","DOI":"10.1038\/s41591-023-02572-5"},{"key":"2963_CR69","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23:1066\u201377.","journal-title":"Lancet Oncol"},{"key":"2963_CR70","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/annonc\/mdr035","volume":"23","author":"E Jantunen","year":"2012","unstructured":"Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012;23:166\u201371.","journal-title":"Ann Oncol"},{"key":"2963_CR71","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2352-3026(21)00195-2","volume":"8","author":"AK Zoellner","year":"2021","unstructured":"Zoellner AK, Unterhalt M, Stilgenbauer S, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8:e648\u2013e657.","journal-title":"Lancet Haematol"},{"key":"2963_CR72","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.bbmt.2017.10.029","volume":"24","author":"YD Tseng","year":"2018","unstructured":"Tseng YD, Stevenson PA, Cassaday RD, et al. Total Body Irradiation is safe and similarly effective as chemotherapy-only conditioning in autologous stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transpl. 2018;24:282\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2963_CR73","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460\u20138.","journal-title":"Lancet Oncol"},{"key":"2963_CR74","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"Chen YB, Lane AA, Logan BR, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21:1046\u201353.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2963_CR75","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1200\/JCO.23.01586","volume":"42","author":"C Sarkozy","year":"2024","unstructured":"Sarkozy C, Thieblemont C, Oberic L, et al. Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA trial: A LYSA Study. J Clin Oncol. 2024;42:769\u201373.","journal-title":"J Clin Oncol"},{"key":"2963_CR76","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","volume":"27","author":"NS Andersen","year":"2009","unstructured":"Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27:4365\u201370.","journal-title":"J Clin Oncol"},{"key":"2963_CR77","unstructured":"Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, and Carreras E. The EBMT handbook. hematopoietic cell transplantation and cellular therapies. Springer. Ref Type: Online Source. 2026 https:\/\/www.ebmt.org\/education\/ebmt-handbook."},{"key":"2963_CR78","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","volume":"54","author":"P Dreger","year":"2019","unstructured":"Dreger P, Michallet M, Bosman P, et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transpl. 2019;54:44\u201352.","journal-title":"Bone Marrow Transpl"},{"key":"2963_CR79","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","volume":"189","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189:684\u20138.","journal-title":"Br J Haematol"},{"key":"2963_CR80","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/2643-3230.BCD-24-0178","volume":"6","author":"N Liebers","year":"2025","unstructured":"Liebers N, Boumendil A, Finel H, et al. Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma. Blood Cancer Discov. 2025;6:182\u201390.","journal-title":"Blood Cancer Discov"},{"key":"2963_CR81","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","volume":"53","author":"SP Robinson","year":"2018","unstructured":"Robinson SP, Boumendil A, Finel H, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transpl. 2018;53:617\u201324.","journal-title":"Bone Marrow Transpl"},{"key":"2963_CR82","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1182\/bloodadvances.2025016315","volume":"9","author":"ZD Epstein-Peterson","year":"2025","unstructured":"Epstein-Peterson ZD, Lionel AC, Joseph A, et al. Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis. Blood Adv. 2025;9:5654\u201362.","journal-title":"Blood Adv"},{"key":"2963_CR83","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3324\/haematol.2022.281242","volume":"108","author":"J Zurko","year":"2023","unstructured":"Zurko J, Ramdial J, Shadman M, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023;108:98\u2013109.","journal-title":"Haematologica"},{"key":"2963_CR84","first-page":"750","volume":"29","author":"P Derigs","year":"2023","unstructured":"Derigs P, Bethge WA, Kramer I, et al. Long-term survivors after failure of CAR-T cell therapy for large B-cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A GLA\/DRST analysis. Transpl Cell Ther. 2023;29:750\u20136.","journal-title":"Transpl Cell Ther"},{"key":"2963_CR85","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbmt.2018.08.025","volume":"25","author":"C Kyriakou","year":"2019","unstructured":"Kyriakou C, Boumendil A, Finel H, et al. The impact of advanced patient age on mortality after allogeneic hematopoietic cell transplantation for non-Hodgkin\u2019s lymphoma: a retrospective study by the EBMT Lymphoma Working Party. Biol Blood Marrow Transpl. 2019;25:86\u201393.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2963_CR86","first-page":"97","volume":"9","author":"NN Shah","year":"2019","unstructured":"Shah NN, Ahn KW, Litovich C, et al. Allogeneic transplantation in elderly patients >\/=65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood. Cancer J. 2019;9:97.","journal-title":"Cancer J"},{"key":"2963_CR87","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/bjh.15721","volume":"184","author":"RJ Lin","year":"2019","unstructured":"Lin RJ, Ho C, Hilden PD, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol. 2019;184:1006\u201310.","journal-title":"Br J Haematol"},{"key":"2963_CR88","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","volume":"19","author":"M Hamadani","year":"2013","unstructured":"Hamadani M, Saber W, Ahn KW, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Centre for International Blood and Marrow Transplant Research. Biol Blood Marrow Transpl. 2013;19:625\u201331.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2963_CR89","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/bjh.70010","volume":"207","author":"A Barone","year":"2025","unstructured":"Barone A, de PC, Stella F, et al. Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: feasibility, safety and survival outcomes. Br J Haematol. 2025;207:956\u201364.","journal-title":"Br J Haematol"},{"key":"2963_CR90","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/leu.2011.11","volume":"25","author":"S Tuve","year":"2011","unstructured":"Tuve S, Gayoso J, Scheid C, et al. Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia. 2011;25:880\u20133.","journal-title":"Leukemia"},{"key":"2963_CR91","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjh.16182","volume":"188","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Boumendil A, Finel H, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2020;188:745\u201356.","journal-title":"Br J Haematol"},{"key":"2963_CR92","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.2217\/fon-2016-0146","volume":"12","author":"MA Kharfan-Dabaja","year":"2016","unstructured":"Kharfan-Dabaja MA, Reljic T, El-Asmar J, et al. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. Future Oncol. 2016;12:2631\u201342.","journal-title":"Future Oncol"},{"key":"2963_CR93","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamaoncol.2020.1278","volume":"6","author":"N Ghosh","year":"2020","unstructured":"Ghosh N, Ahmed S, Ahn KW, et al. Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant. JAMA Oncol. 2020;6:1011\u20138.","journal-title":"JAMA Oncol"},{"key":"2963_CR94","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/bmt.2016.102","volume":"51","author":"B Tessoulin","year":"2016","unstructured":"Tessoulin B, Ceballos P, Chevallier P, et al. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transpl. 2016;51:1184\u201390.","journal-title":"Bone Marrow Transpl"},{"key":"2963_CR95","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41409-020-0976-4","volume":"56","author":"L Selberg","year":"2021","unstructured":"Selberg L, Stadtherr P, Dietrich S, et al. The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis. Bone Marrow Transpl. 2021;56:30\u201337.","journal-title":"Bone Marrow Transpl"},{"key":"2963_CR96","first-page":"973","volume":"31","author":"AM Jimenez Jimenez","year":"2025","unstructured":"Jimenez Jimenez AM, Spellman SR, Politikos I, et al. Allogeneic hematopoietic cell donor selection: contemporary guidelines from the NMDP\/CIBMTR. Transpl Cell Ther. 2025;31:973\u201388.","journal-title":"Transpl Cell Ther"},{"key":"2963_CR97","first-page":"184.e1","volume":"29","author":"A Mussetti","year":"2022","unstructured":"Mussetti A, Kanate AS, Wang T, et al. Haploidentical versus matched unrelated donor transplants using post-transplant cyclophosphamide for lymphomas. Transpl Cell Ther. 2022;29:184.e1\u2013184.e9.","journal-title":"Transpl Cell Ther"},{"key":"2963_CR98","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","volume":"16","author":"G Cook","year":"2010","unstructured":"Cook G, Smith GM, Kirkland K, et al. Outcome following reduced intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle-cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2010;16:1419\u201327.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2963_CR99","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/hon.125_2630","volume":"37","author":"S Robinson","year":"2020","unstructured":"Robinson S, Boumendil A, Finel H, et al. Donor lymphocyte infusions induce durable responses in patients with follicular, mantle and T cell lymphomas relapsing after an alloSCT. An EBMT-LWP study. Hematol Oncol. 2020;37:316\u20137.","journal-title":"Hematol Oncol"},{"key":"2963_CR100","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2025-883","volume":"146","author":"T Phillips","year":"2025","unstructured":"Phillips T, Chen L, Barnhizer T, et al. Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w\/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment. Blood. 2025;146:833.","journal-title":"Blood"},{"key":"2963_CR101","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/bjh.19961","volume":"206","author":"F Stella","year":"2025","unstructured":"Stella F, Chiappella A, Magni M, et al. Brexucabtagene autoleucel in vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: results from the CART-SIE study. Br J Haematol. 2025;206:644\u201351.","journal-title":"Br J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02963-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:03:48Z","timestamp":1789124628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02963-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":101,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2963"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02963-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P Dreger: consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speaker honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. He is the current chairman of the German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy (DAG-HSZT). G Iacoboni\u2014Consulting: Autolus, Bristol-Myers Squibb, Kite\/Gilead, Janssen, Miltenyi, AbbVie, MSD, Regeneron. Honoraria: AbbVie, AstraZeneca, BMS, Kite\/Gilead, Miltenyi, Sobi, Roche, Lilly. Travel support: AbbVie, AstraZeneca, Kite\/Gilead, Miltenyi, Roche. A Bazarbachi: Research support\/Funding: Novartis, Roche, Johnson and Johnson, Hikma and Biologix. S Dietrich: Roche: Advisory board; Kite\/Gilead: Advisory board. TA Eyre: Roche: Honorarium, Advisory Board Honorarium, Trial steering committee; Gilead: Honorarium, Research support, Travel to scientific conferences; Kite\/Gilead: Advisory Board Honorarium; Janssen: Honorarium; AbbVie: Honorarium; Travel to scientific conferences; AstraZeneca: Honorarium, Research funding, Trial steering committee; Loxo Oncology: Advisory Board Honorarium, Trial steering committee; Beigene: Advisory Board Honorarium, Research funding; Incyte: Advisory Board Honorarium, Speaker Honorarium; Autolus: Advisory Board Honorarium; Galapagos: Advisory Board Honorarium; Nurix: Advisory Board Honorarium; BMS: Honorarium, Advisory Board Honorarium, Trial steering committee; Medscape, PeerView, Clinical Care Options, The Limbic Speaker Honorarium. S Ahmed: Research support to the institution for clinical trials from Nektar, Merck, Xencor, Chimagen, Genmab, KITE\/Gilead, Janssen and Caribou. Consultant for ADC Therapeutics, KITE\/Gilead, Genmab and BMS. T Fenske: Consulting\/Advisory: AbbVie, Adaptive Biotechnologies, Ipsen, Pierre Fabre; Speaker\u2019s Bureau: Astrazenca, BeOne (formerly Beigene), Pfizer; Expert witness: Bayer. N Ghosh: Consulting\/Advisory: AbbVie, AstraZeneca, Beigene, BMS, Kite Pharma, Genentech\/Roche, Incyte, Janssen, ADC Therapeutics, Galapagos, Ascentage Pharma. Research funding: Genentech\/Roche, AstraZeneca, AbbVie, Pepromene, Incyte, BMS. M Hamadani: Research Support\/Funding: ADC Therapeutics; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: ADC Therapeutics, BMS, Kite, Genmab, CRISPR, Allovir, Caribou, Autolus, Forte Biosciences, Byondis, Daiichi Sankyo, Incyte. Speaker\u2019s Bureau: AstraZeneca, ADC Therapeutics, BeiGene, Kite, Sobi. I Yakoub-Agha: received honoraria from BMS and Kite\/Gilead. O Hermine: Research support BMS, Blueprint, Consultant AB Science, Inatherys. KiTE\/Gilead, AstraZeneca. F Onida, I Ortega-Sanchez, S Robinson and A Ruggeri declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This manuscript was written by a human without the use of generative AI.","order":2,"name":"Ethics","label":"Declaration of generative AI use","group":{"name":"EthicsHeading","label":"Ethics"}}]}}